256 related articles for article (PubMed ID: 23279695)
21. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation.
Bleeker JS; Gertz MA; Pellikka PA; Larson DR; Buadi F; Dingli D; Dispenzieri A; Hayman SR; Hogan W; Kumar S; Rajkumar SV; Lacy MQ
Eur J Haematol; 2012 Sep; 89(3):228-35. PubMed ID: 22672722
[TBL] [Abstract][Full Text] [Related]
23. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
[TBL] [Abstract][Full Text] [Related]
24. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
25. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
26. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
28. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Lachmann HJ; Wechalekar AD; Gillmore JD
N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
[No Abstract] [Full Text] [Related]
29. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
[TBL] [Abstract][Full Text] [Related]
30. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
[TBL] [Abstract][Full Text] [Related]
31. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
32. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
33. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
[TBL] [Abstract][Full Text] [Related]
34. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.
Leung N; Leung TR; Cha SS; Dispenzieri A; Lacy MQ; Gertz MA
Blood; 2005 Nov; 106(10):3353-7. PubMed ID: 16037390
[TBL] [Abstract][Full Text] [Related]
35. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
36. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
Sanchorawala V; Skinner M; Quillen K; Finn KT; Doros G; Seldin DC
Blood; 2007 Nov; 110(10):3561-3. PubMed ID: 17673601
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
[TBL] [Abstract][Full Text] [Related]
39. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
Kongtim P; Qazilbash MH; Shah JJ; Hamdi A; Shah N; Bashir Q; Wang M; Champlin R; Manasanch EE; Weber D; Orlowski RZ; Parmar S
Bone Marrow Transplant; 2015 May; 50(5):668-72. PubMed ID: 25730192
[TBL] [Abstract][Full Text] [Related]
40. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
